CPT® Code 80410

1. Indications

The calcitonin stimulation panel (CPT® Code 80410) is indicated for the following conditions:

• Medullary Thyroid Cancer (MTC) - This test is performed to help diagnose and monitor the presence and progression of medullary thyroid cancer, a type of thyroid cancer that arises from C-cells.
• Benign C-cell Hyperplasia - The panel is used to evaluate benign growths of C-cells, which can lead to elevated calcitonin levels.
• Multiple Endocrine Neoplasia Type 2 (MEN2) - This genetic condition predisposes individuals to develop MTC and other endocrine tumors, making the calcitonin stimulation test a valuable tool for monitoring at-risk patients.

2. Procedure

The procedure for the calcitonin stimulation panel involves several critical steps to ensure accurate measurement of calcitonin levels:

• Step 1: Establishing an Intravenous Line - An intravenous line is established to facilitate the administration of calcium and/or pentagastrin. This step is essential for the subsequent injections and is considered a separately reportable procedure.
• Step 2: Baseline Calcitonin Measurement - A blood sample is obtained from the established IV line or through a separately reportable venipuncture to measure the baseline level of calcitonin before any stimulation occurs.
• Step 3: Calcium and Pentagastrin Stimulation - For the combined stimulation test, calcium is injected intravenously at a dosage of 2 mg/kg over 1 minute, followed by an intravenous push of pentagastrin at a dosage of 0.5 mcg/kg. Blood samples for calcitonin levels are then collected at 1 and/or 2 minutes, and at 5 minutes post-injection.
• Step 4: Calcium Stimulation Only - If only calcium stimulation is performed, calcium is injected intravenously at a dosage of either 2 mg/kg over 1 minute or 2.4 mg/kg via IV push. Blood samples for calcitonin levels are collected at the same intervals as mentioned above.
• Step 5: Pentagastrin Stimulation Only - In cases where only pentagastrin stimulation is conducted, pentagastrin is injected via IV push at a dosage of 0.5 mg/kg. Blood samples for calcitonin levels are again collected at 1 and/or 2 minutes, and at 5 minutes post-injection.
• Step 6: Testing Serum/Plasma - The collected serum or plasma samples are then tested using a quantitative chemiluminescent immunoassay to determine the levels of calcitonin in response to the stimulation.

3. Post-Procedure

After the completion of the calcitonin stimulation panel, patients may be monitored for any immediate reactions to the intravenous injections. It is important to ensure that the patient is stable before discharge. The results of the calcitonin levels will be analyzed and reported, providing critical information for the diagnosis and management of conditions related to C-cell function and thyroid health. Follow-up appointments may be necessary to discuss the results and any further diagnostic or therapeutic steps that may be required based on the findings.